Tokyo Tape
Sign in
← Taiko Pharmaceutical

Quarterly report · Q3

4574.TEDINET S100S6X1
Period2023-01-01 → 2023-09-30
Filed2023-11-10
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 33
MetricValuePeriodScopeSource row
Revenue¥4.4bn2023-01-01 → 2023-09-30Cons.Net sales
Revenue¥5.0bn2022-01-01 → 2022-12-31Cons.Net sales (5-year summary)
Revenue¥3.4bn2022-01-01 → 2022-09-30Cons.Net sales
Operating income−¥444m2023-01-01 → 2023-09-30Cons.Operating income
Operating income−¥2.8bn2022-01-01 → 2022-09-30Cons.Operating income
Ordinary income−¥589m2023-01-01 → 2023-09-30Cons.Ordinary income
Ordinary income−¥3.4bn2022-01-01 → 2022-12-31Cons.Ordinary income loss (5-year summary)
Ordinary income−¥2.9bn2022-01-01 → 2022-09-30Cons.Ordinary income
Profit before tax−¥537m2023-01-01 → 2023-09-30Cons.Income before income taxes
Profit before tax−¥3.2bn2022-01-01 → 2022-09-30Cons.Income before income taxes
Net income (owners)−¥562m2023-01-01 → 2023-09-30Cons.Profit loss attributable to owners of parent
Net income (owners)−¥4.9bn2022-01-01 → 2022-12-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)−¥3.2bn2022-01-01 → 2022-09-30Cons.Profit loss attributable to owners of parent
Net income−¥562m2023-01-01 → 2023-09-30Cons.Profit loss
Net income−¥3.2bn2022-01-01 → 2022-09-30Cons.Profit loss
Total assets¥15.8bnat 2023-09-30Cons.Assets
Total assets¥15.0bnat 2022-12-31Cons.Assets
Total assets¥16.5bnat 2022-09-30Cons.Total assets (5-year summary)
Total liabilities¥6.0bnat 2023-09-30Cons.Liabilities
Total liabilities¥7.0bnat 2022-12-31Cons.Liabilities
Net assets / equity¥9.8bnat 2023-09-30Cons.Net assets
Net assets / equity¥8.0bnat 2022-12-31Cons.Net assets
Net assets / equity¥9.8bnat 2022-09-30Cons.Net assets (5-year summary)
Cash and deposits¥4.8bnat 2023-09-30Cons.Cash and deposits
Cash and deposits¥3.1bnat 2022-12-31Cons.Cash and deposits
EPS (basic)¥-12.092023-01-01 → 2023-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-0.982023-07-01 → 2023-09-30dCons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-112.262022-01-01 → 2022-12-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-72.972022-01-01 → 2022-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-8.82022-07-01 → 2022-09-30dCons.Basic earnings loss per share (5-year summary)
Equity ratio61.7%at 2023-09-30Cons.Equity to asset ratio (5-year summary)
Equity ratio53.5%at 2022-12-31Cons.Equity to asset ratio (5-year summary)
Equity ratio59.6%at 2022-09-30Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 26
SegmentItemPeriodValue
Reconciling Itemsreconcilingsegment profit2023-01-01 → 2023-09-30−¥738m
jpcrp040300-q3r_E22560-000Infection Control Businessreportable segmentrevenue2023-01-01 → 2023-09-30¥724m
jpcrp040300-q3r_E22560-000Infection Control Businessreportable segmentrevenue external2023-01-01 → 2023-09-30¥724m
jpcrp040300-q3r_E22560-000Infection Control Businessreportable segmentsegment profit2023-01-01 → 2023-09-30−¥643m
jpcrp040300-q3r_E22560-000Other Business Linesreportable segmentrevenue2023-01-01 → 2023-09-30¥4m
jpcrp040300-q3r_E22560-000Other Business Linesreportable segmentrevenue external2023-01-01 → 2023-09-30¥4m
jpcrp040300-q3r_E22560-000Other Business Linesreportable segmentsegment profit2023-01-01 → 2023-09-30−¥17m
jpcrp040300-q3r_E22560-000Pharmaceuticals Businessreportable segmentrevenue2023-01-01 → 2023-09-30¥3.7bn
jpcrp040300-q3r_E22560-000Pharmaceuticals Businessreportable segmentrevenue external2023-01-01 → 2023-09-30¥3.7bn
jpcrp040300-q3r_E22560-000Pharmaceuticals Businessreportable segmentsegment profit2023-01-01 → 2023-09-30¥955m
Total Of Reportable Segments And Otherssegment totalrevenue2023-01-01 → 2023-09-30¥4.4bn
Total Of Reportable Segments And Otherssegment totalrevenue external2023-01-01 → 2023-09-30¥4.4bn
Total Of Reportable Segments And Otherssegment totalsegment profit2023-01-01 → 2023-09-30¥293m
Reconciling Itemsreconcilingsegment profit2022-01-01 → 2022-09-30−¥893m
jpcrp040300-q3r_E22560-000Infection Control Businessreportable segmentrevenue2022-01-01 → 2022-09-30¥976m
jpcrp040300-q3r_E22560-000Infection Control Businessreportable segmentrevenue external2022-01-01 → 2022-09-30¥976m
jpcrp040300-q3r_E22560-000Infection Control Businessreportable segmentsegment profit2022-01-01 → 2022-09-30−¥1.8bn
jpcrp040300-q3r_E22560-000Other Business Linesreportable segmentrevenue2022-01-01 → 2022-09-30¥5m
jpcrp040300-q3r_E22560-000Other Business Linesreportable segmentrevenue external2022-01-01 → 2022-09-30¥5m
jpcrp040300-q3r_E22560-000Other Business Linesreportable segmentsegment profit2022-01-01 → 2022-09-30−¥14m
jpcrp040300-q3r_E22560-000Pharmaceuticals Businessreportable segmentrevenue2022-01-01 → 2022-09-30¥2.4bn
jpcrp040300-q3r_E22560-000Pharmaceuticals Businessreportable segmentrevenue external2022-01-01 → 2022-09-30¥2.4bn
jpcrp040300-q3r_E22560-000Pharmaceuticals Businessreportable segmentsegment profit2022-01-01 → 2022-09-30−¥42m
Total Of Reportable Segments And Otherssegment totalrevenue2022-01-01 → 2022-09-30¥3.4bn
Total Of Reportable Segments And Otherssegment totalrevenue external2022-01-01 → 2022-09-30¥3.4bn
Total Of Reportable Segments And Otherssegment totalsegment profit2022-01-01 → 2022-09-30−¥1.9bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 365
ItemContextValueUnit
Liabilities and net assetsPrior1YearInstant15046000000JPY
Liabilities and net assetsCurrentQuarterInstant15812000000JPY
Net salesPrior1YTDDuration3389000000JPY
Net salesCurrentYTDDuration4417000000JPY
Cost of salesPrior1YTDDuration2912000000JPY
Cost of salesCurrentYTDDuration2626000000JPY
Gross profitPrior1YTDDuration476000000JPY
Gross profitCurrentYTDDuration1791000000JPY
Selling general and administrative expensesPrior1YTDDuration3226000000JPY
Selling general and administrative expensesCurrentYTDDuration2235000000JPY
Operating incomePrior1YTDDuration-2750000000JPY
Operating incomeCurrentYTDDuration-444000000JPY
Interest income noiPrior1YTDDuration2000000JPY
Interest income noiCurrentYTDDuration16000000JPY
Foreign exchange gains noiPrior1YTDDuration107000000JPY
Foreign exchange gains noiCurrentYTDDuration62000000JPY
Restoration contribution income noiPrior1YTDDuration－JPY
Restoration contribution income noiCurrentYTDDuration9000000JPY
Other noiPrior1YTDDuration30000000JPY
Other noiCurrentYTDDuration4000000JPY
Non operating incomePrior1YTDDuration141000000JPY
Non operating incomeCurrentYTDDuration93000000JPY
Interest expenses noePrior1YTDDuration7000000JPY
Interest expenses noeCurrentYTDDuration6000000JPY
Plant shutsdown related costs noePrior1YTDDuration242000000JPY
Plant shutsdown related costs noeCurrentYTDDuration211000000JPY
Other noePrior1YTDDuration38000000JPY
Other noeCurrentYTDDuration21000000JPY
Non operating expensesPrior1YTDDuration289000000JPY
Non operating expensesCurrentYTDDuration238000000JPY
Ordinary incomePrior1YTDDuration-2898000000JPY
Ordinary incomeCurrentYTDDuration-589000000JPY
Gain on sales of noncurrent assets eiPrior1YTDDuration－JPY
Gain on sales of noncurrent assets eiCurrentYTDDuration76000000JPY
Gain on sales of investment securities eiPrior1YTDDuration－JPY
Gain on sales of investment securities eiCurrentYTDDuration87000000JPY
Extraordinary incomePrior1YTDDuration－JPY
Extraordinary incomeCurrentYTDDuration163000000JPY
Loss on sales of noncurrent assets elPrior1YTDDuration0JPY
Loss on sales of noncurrent assets elCurrentYTDDuration－JPY
Loss on retirement of noncurrent assets elPrior1YTDDuration7000000JPY
Loss on retirement of noncurrent assets elCurrentYTDDuration2000000JPY
Premium allowance of retirement elPrior1YTDDuration226000000JPY
Premium allowance of retirement elCurrentYTDDuration－JPY
Impairment loss elPrior1YTDDuration48000000JPY
Impairment loss elCurrentYTDDuration79000000JPY
Loss on valuation of investment securities elPrior1YTDDuration－JPY
Loss on valuation of investment securities elCurrentYTDDuration28000000JPY
Extraordinary lossPrior1YTDDuration282000000JPY
Extraordinary lossCurrentYTDDuration110000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 12 of 12 passed
balance sheet identityconsolidated 2022-12-31pass rounding
balance sheet identityconsolidated 2023-09-30pass
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2022-12-31pass
statement vs summary · net assetsconsolidated 2023-09-30pass
statement vs summary · net income attributable to parentconsolidated 2022-01-01/2022-09-30pass
statement vs summary · net income attributable to parentconsolidated 2023-01-01/2023-09-30pass
statement vs summary · revenueconsolidated 2022-01-01/2022-09-30pass
statement vs summary · revenueconsolidated 2023-01-01/2023-09-30pass
statement vs summary · total assetsconsolidated 2022-12-31pass
statement vs summary · total assetsconsolidated 2023-09-30pass